Leman Biotech
Leman Biotech Co., Ltd, originating from Switzerland, is a clinical-stage innovative immunometabolic drug development company focused on novel tumor immunotherapy drugs. Founded by Professor Li Tang's team from EPFL and JingTai Technology, it leverages immunometabolic reprogramming and advanced AI technologies. The company has developed the Meta 10 platform, showing significant potential to cure solid tumors, with results published in Nature Immunology and multiple global patents. It has a strong R&D team with international experience and is advancing multiple pipelines, including metabolic-enhanced CAR-T cell therapies in clinical trials. Leman Biotech has completed nearly 100 million RMB in angel funding and received over 10 national and regional biotech awards, positioning itself as a leading innovator in tumor immunotherapy.
Leman Biotech
Leman Biotech Co., Ltd, originating from Switzerland, is a clinical-stage innovative immunometabolic drug development company focused on novel tumor immunotherapy drugs. Founded by Professor Li Tang's team from EPFL and JingTai Technology, it leverages immunometabolic reprogramming and advanced AI technologies. The company has developed the Meta 10 platform, showing significant potential to cure solid tumors, with results published in Nature Immunology and multiple global patents. It has a strong R&D team with international experience and is advancing multiple pipelines, including metabolic-enhanced CAR-T cell therapies in clinical trials. Leman Biotech has completed nearly 100 million RMB in angel funding and received over 10 national and regional biotech awards, positioning itself as a leading innovator in tumor immunotherapy.